Advancing bio-printing of living cells for regenerative medicine
EU Funding & Tenders Portal HORIZON-HLTH-2027-03-TOOL-02 · Horizon Europe (HORIZON)
| Funder | European Commission |
|---|---|
| Status | forthcoming |
| Opens | 03 Jun 2027 |
| Deadline | 16 Sep 2027 — 321 days |
| Action | HORIZON Research and Innovation Actions |
| Official page | https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunit… |
| Last checked | 2026-10-30 06:02:40+00:00 |
The scope text was read and no clause in it rules a field out. That is not a guarantee — read the call before you commit to it.
You are reading one call. 1,058 are open right now.
A search matches words. It cannot know what your institution works on. Give the name and every open call is ranked against it — this one included.
This call page is free · no account · the report arrives by emailWhat this call is
| Instrument | HORIZON-RIA |
|---|---|
| Stages | single-stage |
| EU contribution | €7.0m to €10.0m per project |
| Projects expected | 4, sharing €39.3m |
From the Commission's own budget table for this call. Confirm against the topic page before you plan around it: these move when a work programme is amended.
Scope
Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Developing and using new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to most of the following expected outcomes: Biomedical scientists from academia and industry will gain access to entire bio-printing units designed to regenerate human tissue. Healthcare professionals acquire information on the safe and effective use of equipment enabling advanced therapies with bio-printed human tissue. Healthcare providers dispose of tools enabling them to treat conditions of unmet medical need. Individual patients will benefit from a personalised approach to their respective medical condition thanks to the bio-printed regenerative medicine solution. Scope: Tissue-specific functional 3D bio-printing of living cells has made significant progress as a new approach for transplantation applications in regenerative medicine. There are currently several types of bio-printing technologies under development for the repair of different targeted tissues or organs. To fully unleash the potential of bio-printed cell constructs for regenerative medicine several bottlenecks still need to be overcome. Various studies in pre-clinical models have shown that bio-printed cell constructs or tissues hold great promise for regenerative medicine, by allowing autologous tissue grafts being printed thus avoiding adverse graft-host reactions. However, translation of such approaches into clinical settings (i.e. humans) and their application to internal organs still needs to be investigated and demonstrated. Dependant on the actual target site (i.e. the defect tissue or organ in the human body) different bio-printing approaches may be preferable. For printing complex tissues and especially entire organs an in-vitro approach followed by transplantation is the preferred way. “In-situ” bio-printing, sometimes also referred to as “in-vivo”, or as “intraoperative”, reflects a bioprinting process performed on a live subject in a surgical setting and has in certain instances (e.g. tissue repair) advantages over an in-vitro bio-printing technique followed by transplantation. In-situ bio-printing involves direct patterning of bio-inks onto a patient’s body at the target site, allowing for precise construction of a site-matching tissue-structure within the actual physiological location where regeneration or repair is n…
Get told when something changes
Most institutions find out about a call with three weeks left. We write when something opens, moves or closes that fits what you work on, with the deadline, the fit and the funder's own exclusion clauses quoted. Nothing in a quiet week. Free, and one click to leave.
Starting from the programme you are reading: Horizon Europe (HORIZON) — change it below if you like.
Leave the second box empty and you get whatever opened or changed recently, closing soonest. Fill it in and it ranks against your words instead: that is the difference between a list and a shortlist.
Scientific Network Management will send you the current list for these terms, and after that only what changes: a call that opens, a deadline that shifts, a clause that rules you out. Nothing is sent when nothing has moved. One click to stop, in every message.
One confirmation email and nothing else until you click it. No tracking pixels, no sharing, one click to unsubscribe.
Of every 100 Horizon Europe proposals
A funding strategy reads your institution's own published record against the calls that are open, and says in writing which are worth the year and which to decline, with the reason for each.
Scientific Network Management, the grant-writing practice behind this radar: 13 years of EU-funded research projects, and a founder who has served as Key Expert and Team Leader on two EU-funded technical assistance contracts establishing biotechnology centres in Türkiye.
SNM also does
No obligation, and nothing here is conditional on using us: searching the calls stays free and asks for nothing either way.